PharmaShots | Incisive News in 3 Shots

Subscribe Now

AN2 Therapeutics

$AN2 Therapeutics Initiates P-III Part of a P-I/II Study to Evaluate Epetraborole for Treatment-Refractory MAC Lung Disease$

AN2 Therapeutics Initiates P-III Part of a P-I/II Study to Evaluate Epetraborole for Treatment-Refractory MAC Lung Disease

September 26, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us